| Filed On | Filing |
|---|---|
| 10 Feb 2025 |
8-K/A: Financial Statements and Exhibits
We consent to the incorporation by reference in this Current Report of Calidi Biotherapeutics, Inc. on Form 8-K of our report dated March 15, 2024 (except for the effects of the reverse stock split described in Note 1, as to which the da... |
| 24 Oct 2023 |
8-K/A: Departure/Election of Directors or Officers; Compensation
(d) On October 10, 2023, the Company announced the appointment of Mr. Alan R. Stewart as the Class I director of the Company, effective immediately, whose term expires at the first annual meeting of the stockholders of the Company follow... |
Loading...
